Bahar TAŞDELEN, Güliz SARAÇOĞLU, Özlem KANDEMİR, Gürbüz POLAT

The predictive role of AST level, prothrombin time, and platelet count in the detection of liver fibrosis in patients with chronic hepatitis C

Amaç: Kronik hepatit C’de bazı temel serum biyokimyasal testlerinin şiddetli fibrozisi tanımlamada doğruluk derecelerini değelendirmeyi amaçladık. Yöntem ve gereç: Kronik hepatit C enfeksiyonlu 68 hastadan kan örnekleri aspartat minotransferaz, protrombin zamanı ve trombosit sayısı için analiz edildi. Karaciğer histopatolojisi Knodell protokolü kullanılarak değerlendirildi. Serum biyokimyasal belirleyicileri ve stage şiddeti arasındaki ilişki araştırıldı.Bulgular: Fibrozis derecesi ile trombosit sayısı ve GUCI arasındaki ilişki anlamlı bulundu (P < 0,001, P = 0,035, sırayla), ancak APRI ile ([AST/ULN] / Trombosit sayısı [×109 /L]) × 100) (P = 0.052) anlamlı bulunmadı. Trombosit sayısının

Kronik hepatit C’li hastalarda karaciğer fibrozisinin saptanmasında AST seviyesi, protrombin zamanı, ve trombosit sayısının belirleyici rolü

Aim: We aimed to assess the predictive value of a combination some of basic serum biochemical markers for the diagnosis of clinically significant fibrosis in chronic hepatitis C.Materials and Methods: Blood samples from 68 patients with chronic hepatitis C infection were analyzed for aspartate aminotransferase, prothrombin INR, and platelet count. The liver histopathology was evaluated using the Knodell protocol. The relationship between the serum biochemical markers and severity of the stages were examined.Results: A strong association was found between the fibrosis stage and platelet count and GUCI (P < 0.001, P = 0.035 respectively) but not APRI ([AST/ULN] / Platelet count [ ×109 /L]) × 100) (P = 0.052). The relationship between the platelet count

PDF

___

1. Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase to- platelet ratio index for the prediction of hepatitis C-related ibrosis: A systematic review. Hepatology 2007; 46: 912-19.
2. Hepatitis C –global prevalence (update). Wkly Epidemiol Rec 2000; 12: 3682-94.
3. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005; 25: 72-83.
4. Hadziyannis SJ, SetteH Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140: 346-55.
5. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z et al. Impact of pegylated interferonalpha 2b and ribavirin on liver ibrosis in patients with chronic hepatitis C , Gastroenterology 2002; 122: 1303-13.
6. Friedman LS. Controversies in liver biopsy; who, where, when, how, why? Curr Gastroenterol Rep 2004; 6: 30-36.
7. Bedossa P, Dargere D Paradis V. Sampling variability of liver ibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
8. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F et al. Transient elastography: a new noninvasive method for assessment of hepatic ibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
9. Sebestiani G, Alberti A. Non invasive ibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-94.
10. Rockey DC, Bissell DM. Noninvasive measures of liver ibrosis. Hepatology 2006; 43 (2 Suppl 1): 113-20.
11. Lackner C, Struber G, Lieg B, Leibl S, Ofner P, Bankuti C et al. Comparision and validation of simple noninvasive tests foprediction of ibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.
12. Westin J, Ydrborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM et al. A non-invasive ibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol 2008; 43: 73-80.
13. Desmet VJ, Gerber M, Hoofnahgle JH, Manns M, Scheuer P. Classiication of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513–1520.
14. Ono E, Shiratori Y, Okudaira T. Platelet count relects stage of chronic hepatitis C. Hepatol Res 1999; 15: 192-200.
15. Phol A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of ibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-46.
16. Karasu Z, Tekin F, Ersöz G, Gunsar F, Batur Y, Ilter T et al. Liver ibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis C. Dig Dis Sci 2007; 52: 1535-39.
17. Islam S, Antonsson L, Westin J and Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of Standard biochemical serum markers. Scan J Gastroenterol 2005; 40: 867-72.
18. Giannini E, Risso D Botta F, Chiarbonello B, Fasoli A, Malfatti F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus related chronic liver disease. Arch Intern Med 2003; 163: 218-24
19. Fusegawa H, Shiraishi K, Ogasawara F, Shimizu M, Haruki Y, Miyachi H et al. Platelet activation in patients with chronic hepatitis C. Tokai J Exp Clin Med 2002; 27: 101-106
20. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podestà E et al. Serum trombopoietin levels and linked to liver function in untreated patients with hepatitis C virus related chronic hepatitis. J Hepatol 2002; 37: 572-77
21. Coverdale SA, Samarasinghe DA, Lin R, Kench J, Byth K, Khan MH et al. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with ibrotic change in chronic hepatitis C : value for predicting ibrotic progression. Am J Gastroenterol 2003; 98: 1384-90
22. Wai CT, Greenson JK, Fontana RJ, Kalbleisch JD, Marrero JA, Conjeevaram HS et al. A simple noninvasive indexcan predict both signiiciant ibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.